ADAMTS13 levels in a plasma-derived FVIII concentrate: A potential therapeutic option for patients with congenital thrombotic thrombocytopenic purpura

ADAMTS13 levels in a plasma-derived FVIII concentrate: A potential therapeutic option for patients with congenital thrombotic thrombocytopenic purpura

Introduction: Treatment of congenital thrombotic thrombocytopenic purpura (cTTP), a disease characterized by the congenital deficiency of ADAMTS13, remains a challenge as there are no specific treatments available yet, other than therapy based on the use of fresh frozen plasma (FFP). Since cTTP is c...

Full description

Bibliographic Details
Main Authors: Filippo Mori, Ilaria Nardini, Silvia Nannizzi, Roberto Crea, Prasad Mathew, Nicole Ziliotto, Alessandro Gringeri
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Thrombosis Update
Subjects:
ADAMTS13
Thrombotic thrombocytopenic purpura
Plasma-derived FVIII
Online Access:http://www.sciencedirect.com/science/article/pii/S2666572722000244

Similar Items

Similar Items